Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA6 | P23280 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CASP2 | P42575 | 2/20 | 0.48 |
| ▸ | F13A1 | P00488 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | THPO | P40225 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862210 | 1.00 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| SCHEMBL5499167 | 1.00 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3062040 | 0.96 | CASP2 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL174573 | 0.89 | CA12 (0.58) | CA12CA6CA7CA9CA14 | |
| SCHEMBL175639 | 0.87 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL5085745 | 0.87 | CASP2 (0.41) | CA12CA6CA7CA9CA14 | |
| SCHEMBL114607 | 0.86 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| SCHEMBL351230 | 0.86 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| SCHEMBL174695 | 0.86 | CA12 (0.48) | CA12CA6CA7CA9CA14 | |
| SCHEMBL214897 | 0.86 | TDP1 (0.45) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254161-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2005-04-20 | — | — | EP | claimed |
| US-6849709-B2 | Aerothricin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2005-02-01 | — | — | US | claimed |
| EP-1254161-A2 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | Basilea Pharmaceutica AG (CH) | 2002-11-06 | — | — | EP | claimed |
| US-20010031728-A1 | Aerothricin derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2001-10-18 | — | — | US | claimed |
| WO-2001053322-A2 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | claimed |
| EP-1254161-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2005-04-20 | — | — | EP | disclosed |
| US-6849709-B2 | Aerothricin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2005-02-01 | — | — | US | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-1254161-A2 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | Basilea Pharmaceutica AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| US-20010031728-A1 | Aerothricin derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2001-10-18 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001053322-A2 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031728-A1 | Aerothricin derivatives | CIAPIN1, CYP27A1, CYP46A1 | CA12 1936/4885CA6 1076/4885CA7 625/4885 |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | CA12 2313/4885CA6 3310/4885CA7 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.